1. 0058 Scientific Rationale and Clinical Development of AXS-12 for Narcolepsy. (12th April 2019) Authors: O'Gorman, Cedric; Jones, Amanda; Tabuteau, Herriot Journal: Sleep Issue: Volume 42(2019)Supplement 1 Page Start: A24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria. Issue 10 (16th June 2021) Authors: De Mauleon, Adelaide; Ismail, Zahinoor; Rosenberg, Paul; Miller, David; Cantet, Christelle; O'Gorman, Cedric; Vellas, Bruno; Lyketsos, Constantine; Soto, Maria Journal: Alzheimer's & dementia Issue: Volume 17:Issue 10(2021) Page Start: 1687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of AXS‐05, a novel oral NMDA receptor antagonist with multimodal activity in agitation associated with Alzheimer's disease: Results from ADVANCE‐1 — A phase 2/3, double‐blind, active and placebo‐controlled trial: Neuropsychiatry and behavioral neurology/Assessment/Measurement of neuropsychiatric/Behavioral and psychological symptoms. (7th December 2020) Authors: O'Gorman, Cedric; Jones, Amanda; Cummings, Jeffrey L.; Tabuteau, Herriot Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 6 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of AXS‐05, a novel, oral, NMDA‐receptor antagonist with multimodal activity, in agitation associated with Alzheimer's disease: Results from ADVANCE‐1, a phase 2/3, double‐blind, active and placebo‐controlled trial: Developments in clinical trials and cognitive assessment. (7th December 2020) Authors: O'Gorman, Cedric; Jones, Amanda; Cummings, Jeffrey L.; Tabuteau, Herriot Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P2‐033: AXS‐05 (DEXTROMETHORPHAN/BUPROPION): AN INNOVATIVE TREATMENT IN CLINICAL DEVELOPMENT FOR AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE. (1st July 2006) Authors: O'Gorman, Cedric; Jones, Amanda; Tabuteau, Herriot Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 12 Page Start: P679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P3‐020: AXS‐05, A NOVEL ORAL NMDA RECEPTOR ANTAGONIST WITH MULTI‐MODAL ACTIVITY IN CLINICAL DEVELOPMENT FOR AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE. (1st July 2019) Authors: O'Gorman, Cedric; Jones, Amanda; Tabuteau, Herriot Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 18 Page Start: P932 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The humanistic and economic burden of providing care for a patient with schizophrenia. (December 2015) Authors: Csoboth, Csilla; Witt, Edward A; Villa, Kathleen F; O'Gorman, Cedric Journal: International journal of social psychiatry Issue: Volume 61:Number 8(2015) Page Start: 754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗